Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pseudomonas aeruginosa and risk of death and exacerbations in patients with chronic obstructive pulmonary disease: an observational cohort study of 22 053 patients.
Eklöf J, Sørensen R, Ingebrigtsen TS, Sivapalan P, Achir I, Boel JB, Bangsborg J, Ostergaard C, Dessau RB, Jensen US, Browatzki A, Lapperre TS, Janner J, Weinreich UM, Armbruster K, Wilcke T, Seersholm N, Jensen JUS. Eklöf J, et al. Clin Microbiol Infect. 2020 Feb;26(2):227-234. doi: 10.1016/j.cmi.2019.06.011. Epub 2019 Jun 22. Clin Microbiol Infect. 2020. PMID: 31238116 Free article.
The DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork (DECODE-NET): rationale and vision.
Mathioudakis AG, Sivapalan P, Papi A, Vestbo J; DECODE-NET (DisEntangling Chronic Obstructive pulmonary Disease Exacerbations clinical trials NETwork) Investigators. Mathioudakis AG, et al. Eur Respir J. 2020 Jul 2;56(1):2000627. doi: 10.1183/13993003.00627-2020. Print 2020 Jul. Eur Respir J. 2020. PMID: 32616552 Free article. No abstract available.
Inhaled Corticosteroids Particle Size and Risk of Hospitalization Due to Exacerbations and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease. A Nationwide Cohort Study.
Heerfordt CK, Rønn C, Eklöf J, Sivapalan P, Harboe ZB, Hyldgaard C, Fløe A, Mathioudakis AG, Lassen MCH, Biering-Sørensen T, Jensen JS. Heerfordt CK, et al. Among authors: eklof j. Int J Chron Obstruct Pulmon Dis. 2024 Sep 29;19:2169-2179. doi: 10.2147/COPD.S453524. eCollection 2024. Int J Chron Obstruct Pulmon Dis. 2024. PMID: 39364225 Free PMC article.
AM/PM dosing of LAMA for COPD: a randomized controlled trial protocol using digital recruitment and registries.
Sivapalan P, Rømer V, Wirenfeldt Klausen T, Dyrby Johansen N, Pareek M, Modin D, Mathioudakis A, Vestbo J, Eklöf J, Jordan A, Hurst JR, Biering-Sørensen T, Jensen JU. Sivapalan P, et al. Among authors: eklof j. Front Med (Lausanne). 2024 Aug 6;11:1430169. doi: 10.3389/fmed.2024.1430169. eCollection 2024. Front Med (Lausanne). 2024. PMID: 39165373 Free PMC article.
Systemic antibiotics for Pseudomonas aeruginosa infection in outpatients with non-hospitalised exacerbations of pre-existing lung diseases: a randomised clinical trial.
Eklöf J, Alispahic IA, Armbruster K, Lapperre TS, Browatzki A, Overgaard RH, Harboe ZB, Janner J, Moberg M, Ulrik CS, Andreassen HF, Weinreich UM, Kjærgaard JL, Villadsen J, Fenlev CS, Jensen TT, Christensen CW, Bangsborg J, Ostergaard C, Ghathian KSA, Jordan A, Klausen TW, Nielsen TL, Wilcke T, Seersholm N, Sivapalan P, Jensen JS. Eklöf J, et al. Respir Res. 2024 Jun 6;25(1):236. doi: 10.1186/s12931-024-02860-9. Respir Res. 2024. PMID: 38844921 Free PMC article. Clinical Trial.
Individualised treatment of COPD exacerbations using biomarkers.
Sivapalan P, Eklöf J, Bonnesen B, Tønnesen L, Wilcke T, Jensen JS. Sivapalan P, et al. Among authors: eklof j. Ugeskr Laeger. 2024 Apr 1;186(14):V09230560. doi: 10.61409/V09230560. Ugeskr Laeger. 2024. PMID: 38606705 Free article. Review. Danish.
108 results